Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab + docetaxel + gemcitabine as first-line treatment for HER2-positive metastatic breast cancer
2007-003156-11Phase 2Active
- Sponsor
- GOIM
- Start
- Sep 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab, docetaxel and gemcitabine in breast cancer, sponsored by GOIM. Primary endpoint: Objective tumor response. Started Sep 2007; status: active.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-003156-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003156-11.